Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space
New state-of-the-art facility has been designed to support PhoreMost’s phenotypic screening expertise
Collaboration to develop next-generation CAR-T cell therapies with improved efficacy and durability
Lead allosteric PLK1 inhibitor to progress through preclinical and IND enabling studies
inStem’s Centre for Chemical Biology and Therapeutics to work with PhoreMost to progress selected targets
Investment to fund expansion of operations and progression of drug target pipeline
